Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
苍耳子鼻炎胶囊 (Cang'erzi Biyan Jiaonang) is a traditional Chinese medicine (TCM) formulation developed and manufactured by Sichuan Senke Pharmaceutical (Senkeyuan). It is an oral capsule indicated for the treatment of wind-heat type nasal diseases, including acute and chronic rhinitis, allergic rhinitis, and sinusitis. The formulation is composed of several herbal extracts: *Xanthium sibiricum* (Cang'erzi), Gypsum (Shigao), *Angelica dahurica* (Baizhi), *Magnolia biondii* (Xinyihua), and *Scutellaria baicalensis* (Huangqin), supplemented with Borneol and Menthol. Its therapeutic actions include dispersing wind, clearing lung heat, opening nasal passages, and relieving headaches associated with nasal congestion. It is an approved product in China, listed in the National Essential Drugs and National Medical Insurance catalogs.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 苍耳子鼻炎胶囊.